🟢 Eli Lilly is trading 4.6% up today on a new $1.9B genetic medicine deal and a Weight Watchers partnership

Eli Lilly and Company is trading 4.6% up at $1127.99 following the announcement of a major research partnership and expanded access for its weight-loss drug patients.

• The company has entered into a $1.9 billion research collaboration and licensing agreement with Ascidian Therapeutics to discover and develop genetic medicines for kidney diseases.
• Separately, Weight Watchers (WW) announced that its GLP-1 support program is now accessible through Lilly's LillyDirect digital healthcare platform, a move designed to expand patient access and support.
• These developments build on continued investor optimism around the company's aggressive acquisition strategy and the market dominance of its GLP-1 franchise.